Metabolic & weight · Peptide medicine
Also known as Bydureon BCise, Byetta
A GLP-1 receptor agonist used in FDA-approved products for type 2 diabetes. Immediate- and extended-release products have separate labels.[1]
Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific.
Reviewed Jul 22, 2026 · U.S.-focused reference profile
Read the context, not only the compound name. Evidence and status can change with the form, route, population, and use. This profile does not assess individual suitability.
Orientation
Start with identity and research context. Similar names do not establish equivalent products or evidence.
Published research or product contexts. These are not personal indications.
Evidence can change with chemical form, formulation, route, ingredients, and manufacturing. A brand, salt, fragment, or cosmetic ingredient may not represent the same evidence.
What is known
Human studies are available in defined contexts, but the evidence remains product-, population-, route-, or outcome-specific. This is a description, not a rating or recommendation.
GLP-1, metabolic and weight-management
Controlled clinical trials support exenatide products for improving glycemic control in labeled populations with type 2 diabetes.
Evidence and risks vary between immediate- and extended-release formulations. Current market availability can change, and evidence does not support treating unapproved exenatide products as equivalent.
Nonclinical studies supported development and identified product-specific toxicology findings. Such findings are contextual safety evidence, not proof of human benefit.[1]
More human evidence does not automatically transfer to a different product, route, population, or purpose. Limited evidence does not prove no biological activity; it means the relevant clinical question is not established by the reviewed material.
What needs caution
Known published concerns and unanswered questions are kept separate so absence of evidence is never presented as reassurance.
Labeled risks include gastrointestinal reactions, pancreatitis, hypoglycemia with some concomitant medicines, kidney injury, hypersensitivity, and other formulation-specific warnings.
The cited product label describes risks for a specific approved product and use. It is not a complete guide to every product or individual situation.Source [1]Evidence and risks vary between immediate- and extended-release formulations. Current market availability can change, and evidence does not support treating unapproved exenatide products as equivalent.
The answer can change with the product, formulation, route, population, duration, and use being discussed.Source [1]Common effects, important warnings, product-quality concerns, and evidence gaps are different kinds of information. A risk in one product label may not apply to every formulation; an uncertainty proves neither safety nor harm.
Match the product
Form describes the specific product; route describes how it reaches the body. These are sourced descriptions, not instructions.
Prescription subcutaneous injection formulations include immediate- and extended-release products with separate labels.
Routes shown apply only to the named published or investigational formulation; they are not instructions for use.
U.S. product context
At least one FDA-approved product exists, but approval applies only to the named product, formulation, route, population, and use in its label.
Status applies to a product, formulation, route, population, and use. It does not apply to a name in the abstract.
Exenatide is FDA approved in product-specific formulations for labeled use in type 2 diabetes.
Specific form or route not separately published in this record.View sourceTake it forward
Organize a conversation with a qualified professional without creating a treatment recommendation, dose, or protocol.
Organize an existing plan
PeptideGrid can help you organize a schedule and keep dose records together for a plan you already follow. It does not recommend a dose, schedule, or treatment.
Trace the record
Each source supports the section that cites it; publication does not imply endorsement or suitability.
BYETTA prescribing information
DailyMed. BYETTA (exenatide) prescribing information. Revised September 2025.
National Library of Medicine / AstraZeneca · Published Sep 8, 2025 · Accessed Jul 22, 2026 · Prescribing information
Open sourceIdentity, human evidence, laboratory and animal findings, risks, uncertainty, and U.S. product status are shown separately. Missing information stays marked as unpublished instead of being inferred.
